Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 16, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 2,200,000 ordinary shares of 25 pence each.
- Purchase Price: 1,135.1 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.03% of total voting rights).
- Shares in Issue: 5,359,727,796 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,200,000 shares. Consequently, the total number of shares in issue was adjusted to 5,359,727,796. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total number of shares in issue (5,359,727,796) for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (484,194,158) and its impact on total voting rights (9.03%).
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings metrics.